Mechanisms and management of CAR T toxicity

Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. Despite unprecedented efficacy, treatme...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2024-05, Vol.14, p.1396490-1396490
Main Authors: Ferreri, Christopher J, Bhutani, Manisha
Format: Article
Language:English
Subjects:
chimeric antigen receptor (CAR T)
cytokine release syndrome (CRS)
HLH - hemophagocytic lymphohistiocytosis
ICANS - immune effector cell-associated neurotoxicity syndrome
large B cell lymphoma
Oncology
tocilizumab (IL-6 inhibitor)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. Despite unprecedented efficacy, treatment with CAR T cell therapies can cause a multitude of adverse effects which require monitoring and management at specialized centers and contribute to morbidity and non-relapse mortality. Such toxicities include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, neurotoxicity distinct from ICANS, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, and immune effector cell-associated hematotoxicity that can lead to prolonged cytopenias and infectious complications. This review will discuss the current understanding of the underlying pathophysiologic mechanisms and provide guidelines for the grading and management of such toxicities.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1396490